CMScaller: an R Package for Consensus Molecular Subtyping of Colorectal Cancer Pre-clinical Models

Overview

Journal Sci Rep

Specialty Science

Date 2017 Dec 2

PMID 29192179

Citations 180

Authors

Peter W Eide

Jarle Bruun

Ragnhild A Lothe

Anita Sveen

Affiliations

Soon will be listed here.

Abstract

Colorectal cancers (CRCs) can be divided into four gene expression-based biologically distinct consensus molecular subtypes (CMS). This classification provides a potential framework for stratified treatment, but to identify novel CMS-drug associations, translation of the subtypes to pre-clinical models is essential. The currently available classifier is dependent on gene expression signals from the immune and stromal compartments of tumors and fails to identify the poor-prognostic CMS4-mesenchymal group in immortalized cell lines, patient-derived organoids and xenografts. To address this, we present a novel CMS classifier based on a filtered set of cancer cell-intrinsic, subtype-enriched gene expression markers. This new classifier, referred to as CMScaller, recapitulated the subtypes in both in vitro and in vivo models (551 in total). Importantly, by analyzing public drug response data from patient-derived xenografts and cell lines, we show that the subtypes are predictive of response to standard CRC drugs. CMScaller is available as an R package.

Citing Articles

Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer.

Yang M, Nebozhyn M, Schell M, Gandhi N, Pflieger L, Loboda A BMC Cancer. 2025; 25(1):441.

PMID: 40075322 PMC: 11899100. DOI: 10.1186/s12885-025-13829-2.

Repurposing pitavastatin and atorvastatin to overcome chemoresistance of metastatic colorectal cancer under high glucose conditions.

Cheng W, Li P, Nguyen M, Lin Y, Huang Y, Cheng T Cancer Cell Int. 2025; 25(1):79.

PMID: 40050889 PMC: 11887183. DOI: 10.1186/s12935-025-03712-2.

Immune profiling of the macroenvironment in colorectal cancer unveils systemic dysfunction and plasticity of immune cells.

Ke H, Li P, Li Z, Zeng X, Zhang C, Luo S Clin Transl Med. 2025; 15(2):e70175.

PMID: 39934971 PMC: 11813809. DOI: 10.1002/ctm2.70175.

Comprehensive characterization of micropapillary colorectal adenocarcinoma.

Aijala V, Harkonen J, Mantere T, Elomaa H, Sirnio P, Pohjanen V J Pathol. 2025; 265(4):408-421.

PMID: 39917902 PMC: 11880967. DOI: 10.1002/path.6392.

Consensus molecular subtyping of colorectal carcinoma brain metastases reveals a metabolic signature associated with poor patient survival.

Irmer B, Wlochowitz D, Krekeler C, Richter K, Chandrabalan S, Bayerlova M Mol Oncol. 2025; 19(3):614-634.

PMID: 39825568 PMC: 11887667. DOI: 10.1002/1878-0261.13748.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Fujii M, Shimokawa M, Date S, Takano A, Matano M, Nanki K . A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. Cell Stem Cell. 2016; 18(6):827-838. DOI: 10.1016/j.stem.2016.04.003. View

Sandberg R, Larsson O . Improved precision and accuracy for microarrays using updated probe set definitions. BMC Bioinformatics. 2007; 8:48. PMC: 1805763. DOI: 10.1186/1471-2105-8-48. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Kolesnikov N, Hastings E, Keays M, Melnichuk O, Tang Y, Williams E . ArrayExpress update--simplifying data submissions. Nucleic Acids Res. 2014; 43(Database issue):D1113-6. PMC: 4383899. DOI: 10.1093/nar/gku1057. View

Bramsen J, Heilskov Rasmussen M, Ongen H, Mattesen T, Worm Orntoft M, Arnadottir S . Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer. Cell Rep. 2017; 19(6):1268-1280. DOI: 10.1016/j.celrep.2017.04.045. View

Isella C, Brundu F, Bellomo S, Galimi F, Zanella E, Porporato R . Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat Commun. 2017; 8:15107. PMC: 5499209. DOI: 10.1038/ncomms15107. View

Heimberg G, Bhatnagar R, El-Samad H, Thomson M . Low Dimensionality in Gene Expression Data Enables the Accurate Extraction of Transcriptional Programs from Shallow Sequencing. Cell Syst. 2016; 2(4):239-250. PMC: 4856162. DOI: 10.1016/j.cels.2016.04.001. View

Tauriello D, Calon A, Lonardo E, Batlle E . Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017; 11(1):97-119. PMC: 5423222. DOI: 10.1002/1878-0261.12018. View

10.

Wu D, Smyth G . Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 2012; 40(17):e133. PMC: 3458527. DOI: 10.1093/nar/gks461. View

11.

Croft D, Mundo A, Haw R, Milacic M, Weiser J, Wu G . The Reactome pathway knowledgebase. Nucleic Acids Res. 2013; 42(Database issue):D472-7. PMC: 3965010. DOI: 10.1093/nar/gkt1102. View

12.

Bracht K, Nicholls A, Liu Y, Bodmer W . 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. Br J Cancer. 2010; 103(3):340-6. PMC: 2920028. DOI: 10.1038/sj.bjc.6605780. View

13.

Sadanandam A, Lyssiotis C, Homicsko K, Collisson E, Gibb W, Wullschleger S . A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013; 19(5):619-25. PMC: 3774607. DOI: 10.1038/nm.3175. View

14.

Fessler E, Jansen M, De Sousa E Melo F, Zhao L, Prasetyanti P, Rodermond H . A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype. Oncogene. 2016; 35(46):6026-6037. PMC: 5116560. DOI: 10.1038/onc.2016.134. View

15.

van de Wetering M, Francies H, Francis J, Bounova G, Iorio F, Pronk A . Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015; 161(4):933-45. PMC: 6428276. DOI: 10.1016/j.cell.2015.03.053. View

16.

Song N, Pogue-Geile K, Gavin P, Yothers G, Kim S, Johnson N . Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. JAMA Oncol. 2016; 2(9):1162-9. PMC: 5065181. DOI: 10.1001/jamaoncol.2016.2314. View

17.

Pauli C, Hopkins B, Prandi D, Shaw R, Fedrizzi T, Sboner A . Personalized and Cancer Models to Guide Precision Medicine. Cancer Discov. 2017; 7(5):462-477. PMC: 5413423. DOI: 10.1158/2159-8290.CD-16-1154. View

18.

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View

19.

Hansen K, Irizarry R, Wu Z . Removing technical variability in RNA-seq data using conditional quantile normalization. Biostatistics. 2012; 13(2):204-16. PMC: 3297825. DOI: 10.1093/biostatistics/kxr054. View

20.

Sottoriva A, Kang H, Ma Z, Graham T, Salomon M, Zhao J . A Big Bang model of human colorectal tumor growth. Nat Genet. 2015; 47(3):209-16. PMC: 4575589. DOI: 10.1038/ng.3214. View